Weight-loss patients voice concerns as CVS Caremark drops Zepbound coverage for Wegovy, though exceptions may exist for those ...

San Francisco telehealth company Hims & Hers saw its stock plunge more than 30% earlier this week after a partnership with ...

The number of U.S. adults that are aware of GLP-1 drugs used for weight loss, such as Ozempic and Wegovy, has jumped ...

While Novo Nordisk blamed rival drugs and its own tepid expansion for downgrades to sales and profit growth, some analysts ...

Weight loss medications like Wegovy can be life-changing for people living with obesity or excess weight with related health ...

Shares in Novo Nordisk fell as much as 6% on Friday before recovering some ground later in the session, extending recent ...

A U.S. ban on copycat versions of Novo Nordisk's Wegovy has begun to lift use of the weight loss drug, but the company will ...

Heston Blumenthal has revealed that he is taking the weight-loss drug Wegovy. The celebrity chef admitted his use of the drug ...

Pedersen, Stine Jacobsen and Maggie Fick COPENHAGEN (Reuters) -Investors knocked $70 billion off Novo Nordisk's market value ...

Popular weight loss drugs like Wegovy and Ozempic could increase the risk of stomach paralysis as well as several other serious gastrointestinal conditions, according to a study published in JAMA.

Wegovy is designed to be taken once a week by self-injection. Patients start on the lowest dose, 0.25 milligrams, and move up to the maintenance dose, 2.4 milligrams, over the course of 16 weeks.